Welcome to BioSeeker Group!

Triple Analysis: Melanoma, Cancer Vaccines and Peptides

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3201
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Melanoma, Cancer Vaccines and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Cancer Vaccines and Peptides.

    To find out more about Triple Analysis: Melanoma, Cancer Vaccines and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Cancer Vaccines and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part II: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part II: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
3SBio
7TM Pharma
AB Science
Abbott
AbbVie
Abiogen
AC Immune
Acceleron Pharma
Actelion
Adaptimmune
Adherex
Advanced Life Sciences
Advaxis
AEterna Zentaris
Affymax
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Allostera
Allosterix
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apotex
Ardana
Argos Therapeutics
Ariad
ArQule
Array BioPharma
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Bio-Medisinsk Innovasjon
BioAlliance Pharma
Biogen Idec
Biokine Therapeutics
BioNTech
BioNumerik
BioSante
Biosceptre
Biostar
Biotech Ltd
Biotecnol
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celgene
Celldex Therapeutics
Celtic Pharma
Center of Molecular Immunology
CG Therapeutics
Chemokine Therapeutics
Chiasma
CJ Corp
Clavis Pharma
Cleveland BioLabs
Clinuvel
Compugen
Cosmo Pharmaceuticals
CreaGene
CSL
Curaxis
CureTech
CureVac
Cyclacel
CytImmune Sciences
Cytokinetics
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
Digna Biotech
DNAVEC
Dong-A
Dongkook Pharm
Eisai
Eli Lilly
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Esperance Pharmaceuticals
Etubics
Exelixis
Flamel Technologies
Formula Pharmaceuticals
Galena Biopharma
Generex
Genmab
GenOdyssee Pharmaceuticals
GENova Biotherapeutics
Genovax
Genta
Genticel
GenVec
Geron
GlaxoSmithKline
Glide Pharma
Gliknik
GlobeImmune
GP Pharm
Gradalis
Gryphon Therapeutics
Heat Biologics
Hemispherx Biopharma
Hoffmann-La Roche
Ichor Medical Systems
Idera Pharmaceuticals
immatics biotechnologies
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunotope
Immunovaccine
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inotek
Inovio
Intas Biopharmaceuticals
Intracel
Intrexon
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Kalypsys
Karyon-CTT
Kiadis
Kirax
Lee’s Pharmaceutical
Leo
LG Life Sciences
Ligand
Lipotek
Mannkind
Marillion Pharmaceuticals
MBiotec
Meda
MediGene
Mediolanum
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Momotaro-Gene
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Neurobiological Technologies
Nidus Laboratories
NIH
Non-industrial source
Northwest Biotherapeutics
Novartis
NovaRx
Novogen
NPS Pharmaceuticals
Oasmia
Oncalis
OncoMune
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
Oxford BioMedica
Pacific Biotech
Patrys
PBL Therapeutics
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
PharmaForm
PharmaGap
PharmaMar
Pharmexa
PhiloGene
Pierre Fabre
Piramal
Progen
Progenics Pharmaceuticals
Protagonist
Protherics
Q Chip
QLT
Radient Pharmaceuticals
Raptor Pharmaceutical
Reata Pharmaceuticals
Receptor BioLogix
Regulon
Reliance Life Sciences
responsif
Rexahn
Sanofi
Santaris Pharma
Santhera Pharmaceuticals
Sarepta Therapeutics
Sareum
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Serometrix
Shionogi
Shire
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Soligenix
Spectrum Pharmaceuticals
Spirogen
Sunesis
Swedish Orphan Biovitrum
Synta Pharmaceuticals
Tactic Pharma
Takeda
Tapestry Pharmaceuticals
TapImmune
Targa Therapeutics
Targepeutics
Tau Therapeutics
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
to-BBB
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
Unigene
United Biomedical
Vaccinex
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VBL Therapeutics
Vectura
Vical
Wilex
VioQuest
Viragen
Virionics
ViroMed
WntResearch
Xerion
Xigen
York Pharma
Zelos Therapeutics
Zensun
Zydus Cadila
A Shortlist of Drugs Included are:
A6
abagovomab
abarelix
ABT-510
ADXS11-001
AE-37
AEB071
AEZS-108
afamelanotide
agatolimod
AGS-003
aldesleukin
ALT-801
angiopep+paclitaxel
ANZ-207
APO-866
ARRY-438162
astuprotimut-r
Auto TAG vaccine
AVX-701
axitinib
bardoxolone methyl
belagenpumatucel-L
belinostat
bevacizumab
BMS-663513
BMS-936558
bortezomib
BP-GMAX-CD1
Buparlisib
BV-NSCLC-001
Cabozantinib
CB-10-01
CBP-501
CDX-1307
CG-201
cilengitide
corticorelin acetate
cositecan
CreaVax-PC
CT-011
CV-9103
CV-9201
CVac
dasatinib
DCVax-prostate
decitabine
denenicokin
denileukin diftitox
deslorelin
dinaciclib
dovitinib lactate
E-75
E7449
EMD-273063
emepepimut-S
endostatin
entinostat
EP-100
epirubicin
everolimus
Exherin
FPI-01
fresolimumab
ganetespib
ganitumab
gefitinib
GI-4000
glembatumumab vedotin
golvatinib
goserelin
GSK-1120212
GSK-2118436
GSK-2130579A
GV-1001
GVAX
GVX-3322
GX-301
Her-2/Neu peptides
Hi-8 MEL
histamine dihydrochloride
histrelin
HS-110
ICT-107
imatinib mesilate
imMucin
IMO-2055
INCB-24360
interferon
interleukin-12
interleukin-2
intetumumab
IPH-1101
ipilimumab
IPP-204106
ISA-P53-01
ispinesib mesylate
JX-594
kahalalide F
L19-IL2
Lambrolizumab
lanreotide
LEE-011
lenvatinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
LGX818
LipoVIL12
MDX-1379
MetXia
MGN-1601
MKC-1106-MT
MORAb-004
MVA-BN Her-2 vaccine
NAFB001
netupitant
nilotinib
octreotide
octreotide, LAR
OncoVAX
Onyvax-105
OTS-102
ozarelix
p.DOM-WT1-37/p.DOM-WT1-126 DNA
P276-00
pasireotide
pasireotide LAR
peginterferon alfa-2b
perifosine
pimasertib
plitidepsin
poly-ICLC
polyclonal antibody stimulator
PROSTVAC
PSMA ADC
RAF-265
ramucirumab
retaspimycin
Reximmune-C
rhIFN-alpha
ridaforolimus
rindopepimut
rintatolimod
romurtide
S-488410
sagopilone
sargramostim
SCIB-1
selumetinib
sipuleucel-T
sotatercept
sunitinib malate
Survivac
talminogene laherparepvec
tesetaxel
TG-4010
thalidomide
thymalfasin
tipapkinogene sovacivec
TM-30339
trabedersen
tremelimumab
TroVax
vapreotide, immediate-release
velimogene aliplasmid
veliparib
vemurafenib
verpasep caltespen
verubulin
vinflunine ditartrate
vitespen
volociximab
VX-001
YM-155
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Cancer Vaccines and Peptides.
    To find out more about Triple Analysis: Melanoma, Cancer Vaccines and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Cancer Vaccines and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Leukemia and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Leukemia and Pancreatic Cancer. Learn More


Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Prostate Cancer and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Melanoma, Pancreatic Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the compound strategy of Antibodies. Learn More


Triple Analysis: Leukemia, Prostate Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Leukemia and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More